The combination of VEGF inhibitors and HIF blockade in glioblastoma has not yet been comprehensively evaluated in any clinical trial; it is a hypothesis supported only by preclinical data and known mechanisms, and more comprehensive clinical studies are needed in this area. This evidence concerns the gene VEGFA and glioblastoma.